

COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

WEST COAST HIV VIRTUAL UPDATE, JUNE 29, 2020

Course Chairs	
Monica Gandhi, MD, MPH Professor of Medicine University of California San Francisco San Francisco, California	<i>Dr Gandhi has no relevant financial affiliations to disclose. (Updated 01/19/20)</i>
Robert T. Schooley, MD Professor and Vice Chair of Medicine University of California San Diego La Jolla, California	<i>Dr Schooley has served as a consultant to CytoDyn, AbbVie and Sempra Energy; stock options in Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; has serves on data and safety monitoring boards for Gilead Sciences, Inc., and VIR. His spouse serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 06/08/20)</i>
Speakers	
Constance A. Benson, MD Professor of Medicine and Global Public Health University of California San Diego La Jolla, California	<i>Dr Benson has served on advisory and data monitoring boards for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. Her spouse has served as a consultant to CytoDyn; has received royalties from Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; has serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. (Updated 06/26/20)</i>
Connie L. Celum, MD, MPH Professor of Medicine and Global Health Adjunct Professor of Epidemiology University of Washington Seattle, Washington	<i>Dr Celum has served as a scientific advisor to Merck & Co, Inc. and Gilead Sciences Inc. (Updated 02/06/20)</i>
Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California	<i>Dr Daar has served as a consultant for Gilead Sciences, Inc, and has received research Support from Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare (Updated 06/26/20)</i>
Ferric C. Fang, MD Professor of Laboratory Medicine University of Washington Seattle, Washington	<i>Dr Fang has served as a consultant for Cepheid, BioFire, Armata, and 30 Technologies. He has a grant pending from BioFire. (Updated 05/03/20)</i>
IAS–USA CME Planners and Reviewers	
Donna M. Jacobsen Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/29/20)</i>
Monica Gandhi, MD, MPH	<i>Dr Gandhi has no relevant financial affiliations to disclose. (Updated 01/19/20)</i>
Robert T. Schooley, MD	<i>Dr Schooley has served as a consultant to CytoDyn; has received royalties from Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; has serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. His spouse serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 02/20/20)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.	